SLDB news, real time SLDB stock news, Solid Bioscience news today

News

SLDB

6.93

+1.02%

0.07

Solid Biosciences (SLDB) Gets a Buy from Wedbush

TipRanks · 8h ago

Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones

Seeking Alpha · 22h ago

Solid Biosciences Price Target Maintained With a $16.00/Share by Needham

Dow Jones · 1d ago

Needham Reiterates Buy on Solid Biosciences, Maintains $16 Price Target

Benzinga · 1d ago

Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26

NASDAQ · 1d ago

Solid Bio aligns with FDA on late-stage trial design for Duchenne drug

Seeking Alpha · 1d ago

Solid Biosciences reaches FDA alignment on IMPACT DUCHENNE study design

TipRanks · 1d ago

Reiterating Buy on Solid Biosciences: Conviction in Next‑Generation DMD Gene Therapy and Favorable Risk‑Reward

TipRanks · 1d ago

Solid Biosciences Announces Positive Regulatory Update From Type C Meeting With FDA Supporting Continued Advancement Of SGT-003 As Potential Treatment For Duchenne Muscular Dystrophy

Benzinga · 1d ago

Solid Biosciences Announces FDA Alignment on Phase 3 Trial Design for SGT-003 in Duchenne Muscular Dystrophy

Reuters · 1d ago

Solid Biosciences startet Phase-3-Studie mit SGT-003 gegen Duchenne-Muskeldystrophie

Reuters · 1d ago

SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9

Reuters · 1d ago

Weekly Report: what happened at SLDB last week (0202-0206)?

Weekly Report · 1d ago

Solid Biosciences Leadership Quietly Unloads a Wave of Insider Shares

TipRanks · 3d ago

Solid Biosciences COO David T. Howton Reports Disposal of Common Shares

Reuters · 3d ago

Solid Biosciences CEO Alexander Cumbo Reports Disposal of Common Shares

Reuters · 3d ago

Solid Biosciences CFO Kevin Tan Reports Disposal of Common Shares

Reuters · 3d ago

Solid Biosciences CTO Paul Herzich Reports Sale of Common Shares

Reuters · 3d ago

Solid Biosciences participates in a conference call with William Blair

TipRanks · 4d ago

Solid Biosciences CEO to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters · 4d ago

Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.

About SLDB

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.